全球消化性潰瘍藥物市場－產業規模、佔有率、趨勢、機會和預測，依產品類型、疾病適應症、配銷通路、地區和競爭格局分類，2020-2030年預測

全球消化性潰瘍藥物市場規模預計將從2024年的35.4億美元成長至2030年的43.1億美元，年複合成長率為3.32%。消化性潰瘍藥物是指用於治療胃、小腸或食道內壁潰瘍的藥物，這些潰瘍主要由幽門螺旋桿菌感染或長期使用非類固醇抗發炎藥物引起。市場擴張的主要促進因素是全球幽門螺旋桿菌感染率的上升以及非類固醇抗發炎藥物的廣泛使用。

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球消化性潰瘍藥物市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依產品類型（質子幫浦抑制劑、鉀競爭性酸阻斷劑 (P-CAB)、制酸劑、H2-拮抗劑、抗生素、潰瘍保護劑）
  • 依疾病適應症分類（胃炎、胃潰瘍、十二指腸潰瘍、胃食道逆流（GERD））
  • 按配銷通路（醫院藥房、零售藥房、電子商務）
  • 按地區
  • 按公司（2024 年）
• 市場地圖

第6章：北美消化性潰瘍藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲消化性潰瘍藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區消化性潰瘍藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東與非洲消化性潰瘍藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲消化性潰瘍藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章：市場動態

• 促進要素
• 挑戰

第12章：市場趨勢與發展

• 併購（如有）
• 產品發布（如有）
• 最新進展

第13章：全球消化性潰瘍藥物市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客的力量
• 替代產品的威脅

第15章：競爭格局

• Daewoong Pharmaceutical Co., Ltd
• Takeda Pharmaceutical Co., Ltd.
• Pfizer Inc.
• AstraZeneca plc.
• RedHill Biopharma Ltd.
• Zydus Lifesciences Limited
• ANI Pharmaceuticals, Inc. (Novitium Pharma LLC.)
• Boehringer Ingelheim International GmbH
• Eisai Co. Ltd.
• Yuhan Corporation

第16章：策略建議

第17章調查會社について,免責事項

The Global Peptic Ulcer Drugs Market will grow from USD 3.54 Billion in 2024 to USD 4.31 Billion by 2030 at a 3.32% CAGR. Peptic ulcer drugs comprise pharmaceutical agents formulated to treat open sores that develop on the lining of the stomach, small intestine, or esophagus, primarily resulting from *Helicobacter pylori* infection or prolonged use of nonsteroidal anti-inflammatory drugs. The market's expansion is fundamentally driven by the escalating global prevalence of *H. pylori* infections and the extensive use of NSAIDs.

Key Market Drivers

The global peptic ulcer drugs market is significantly driven by the persistent high incidence of *Helicobacter pylori* infection. This bacterium is a primary etiological factor for peptic ulcer disease, necessitating targeted antimicrobial and acid-suppressing therapies for successful eradication and healing. The widespread nature of this infection ensures a continuous and substantial patient pool requiring diagnostic procedures and a comprehensive array of pharmaceutical interventions.

Key Market Challenges

A significant impediment to the sustained expansion of the global peptic ulcer drugs market is the escalating antibiotic resistance encountered in *Helicobacter pylori* eradication regimens. This challenge directly undermines the effectiveness of established first-line therapies, leading to suboptimal patient outcomes. When bacteria develop resistance to antibiotics, the standard treatment protocols become less efficacious, often necessitating longer treatment durations, the use of more complex drug combinations, or the administration of higher doses, all of which increase treatment burden and healthcare costs.

Key Market Trends

The global peptic ulcer drugs market is experiencing a significant shift towards Potassium-Competitive Acid Blockers (P-CABs), marking an advancement in acid suppression therapy. P-CABs offer benefits such as rapid onset and consistent acid suppression, addressing limitations of traditional proton pump inhibitors. Their integration into treatment protocols is expanding, especially for patients unresponsive to conventional therapies. According to the American Gastroenterological Association's Clinical Practice Update, published in January 2025, P-CABs are recommended in place of proton pump inhibitors for most patients with *Helicobacter pylori* and other conditions where initial therapies have failed.

Key Market Players

• Daewoong Pharmaceutical Co., Ltd
• Takeda Pharmaceutical Co., Ltd.
• Pfizer Inc.
• AstraZeneca plc.
• RedHill Biopharma Ltd.
• Zydus Lifesciences Limited
• ANI Pharmaceuticals, Inc. (Novitium Pharma LLC.)
• Boehringer Ingelheim International GmbH
• Eisai Co. Ltd.
• Yuhan Corporation

Report Scope:

In this report, the Global Peptic Ulcer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peptic Ulcer Drugs Market, By Product Type:

• Proton Pump Inhibitors
• Potassium-Competitive Acid Blocker (P-CAB)
• Antacids
• H2- Antagonist
• Antibiotics
• Ulcer Protective

Peptic Ulcer Drugs Market, By Disease Indication:

• Gastitis
• Gastric Ulcer
• Duodenal Ulcer
• Gastroesophageal Reflux Disease (GERD)

Peptic Ulcer Drugs Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce

Peptic Ulcer Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Peptic Ulcer Drugs Market.

Available Customizations:

Global Peptic Ulcer Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Peptic Ulcer Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Proton Pump Inhibitors, Potassium-Competitive Acid Blocker (P-CAB), Antacids, H2- Antagonist, Antibiotics, Ulcer Protective)
  • 5.2.2. By Disease Indication (Gastitis, Gastric Ulcer, Duodenal Ulcer, Gastroesophageal Reflux Disease (GERD))
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Peptic Ulcer Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Disease Indication
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Peptic Ulcer Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Disease Indication
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Peptic Ulcer Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Disease Indication
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Peptic Ulcer Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Disease Indication
      • 6.3.3.2.3. By Distribution Channel

7. Europe Peptic Ulcer Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Disease Indication
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Peptic Ulcer Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Disease Indication
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Peptic Ulcer Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Disease Indication
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Peptic Ulcer Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Disease Indication
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Peptic Ulcer Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Disease Indication
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Peptic Ulcer Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Disease Indication
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Peptic Ulcer Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Disease Indication
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Peptic Ulcer Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Disease Indication
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Peptic Ulcer Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Disease Indication
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Peptic Ulcer Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Disease Indication
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Peptic Ulcer Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Disease Indication
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Peptic Ulcer Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Disease Indication
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Peptic Ulcer Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Disease Indication
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Peptic Ulcer Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Disease Indication
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Peptic Ulcer Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Disease Indication
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Peptic Ulcer Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Disease Indication
      • 9.3.3.2.3. By Distribution Channel

10. South America Peptic Ulcer Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Disease Indication
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Peptic Ulcer Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Disease Indication
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Peptic Ulcer Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Disease Indication
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Peptic Ulcer Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Disease Indication
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Peptic Ulcer Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Daewoong Pharmaceutical Co., Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Takeda Pharmaceutical Co., Ltd.
• 15.3. Pfizer Inc.
• 15.4. AstraZeneca plc.
• 15.5. RedHill Biopharma Ltd.
• 15.6. Zydus Lifesciences Limited
• 15.7. ANI Pharmaceuticals, Inc. (Novitium Pharma LLC.)
• 15.8. Boehringer Ingelheim International GmbH
• 15.9. Eisai Co. Ltd.
• 15.10. Yuhan Corporation

16. Strategic Recommendations

17. About Us & Disclaimer